Zetia vs Repatha: Switching Between Them and What Women Need to Know

The Core Question: Which Drug Does More for Your Heart?

Repatha (evolocumab) produces a larger absolute LDL reduction and a greater reduction in cardiovascular events than Zetia (ezetimibe). That is the short answer. The longer answer is that these two drugs work differently, cost very differently, and are used at different points in the treatment ladder. For many women, the question is not which one is "better" in isolation, it is which one belongs in your current regimen, given your risk level, your life stage, and what your LDL is actually doing right now.

There is no published head-to-head randomized trial comparing ezetimibe directly against evolocumab on cardiovascular outcomes. What exists are two separate landmark trials, each adding one drug to background statin therapy, with different patient populations. Reading them side by side tells you a great deal, but the comparison is indirect.

How Each Drug Works

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50 percent. It is a pill taken once daily.

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, the protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the liver surface, pulling more LDL-C out of circulation. It is injected under the skin.

What the Trials Actually Show

The IMPROVE-IT trial enrolled 18,144 patients after acute coronary syndrome and added ezetimibe 10 mg or placebo to simvastatin 40 mg. Over a median of 6 years, the ezetimibe group achieved a 6.4 percent relative reduction in the primary composite MACE endpoint compared with placebo. Absolute risk reduction was 2 percentage points (34.7% vs 32.7%). LDL fell from a mean of 93.8 mg/dL to 69.5 mg/dL in the ezetimibe arm.

The FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already on optimized statin therapy and added evolocumab or placebo. Over a median of 2.2 years, evolocumab reduced the primary endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15 percent relative risk. LDL fell from a median of 92 mg/dL to 30 mg/dL, a 59 percent reduction.

The populations differ: IMPROVE-IT was post-ACS; FOURIER was broader established ASCVD. Trial duration differed. Statin background differed. Direct comparison of percentage MACE reductions across these trials cannot substitute for a true head-to-head study.

LDL Lowering: What the Numbers Mean for Women

Women are not a homogeneous group in lipid trials, and both IMPROVE-IT and FOURIER included women but did not power sex-specific subgroup analyses with enough precision to give definitive sex-differentiated outcomes.

A practical framework for women by life stage:

Reproductive Years (Ages 18 to 40)

Estrogen generally keeps LDL lower and HDL higher during the reproductive years. Cardiovascular risk is lower on average, but women with familial hypercholesterolemia (FH), PCOS, or type 2 diabetes carry elevated baseline risk regardless of age. PCOS is associated with an atherogenic lipid profile, including higher LDL, lower HDL, and elevated triglycerides, independent of BMI. Women with PCOS who require lipid therapy may need ezetimibe added to a statin earlier than their peers without PCOS.

Perimenopause (Typically Ages 40 to 55)

LDL rises sharply in the late perimenopause transition, sometimes by 10 to 15 percent, driven by falling estrogen. One longitudinal analysis from the SWAN cohort found that LDL increased by approximately 9 mg/dL during the final menstrual period transition. This is the stage where many women who were at borderline risk cross into higher-risk territory and need a lipid treatment review. If a statin alone is no longer meeting your LDL goal, this is often when ezetimibe is added first, and when the question of escalation to a PCSK9 inhibitor becomes relevant.

Post-Menopause

Post-menopausal women have cardiovascular event rates that approach those of men of similar age. Women in this group with established ASCVD, or very high-risk primary prevention (LDL above 190 mg/dL, familial hypercholesterolemia, diabetes with target organ damage), are the most likely candidates for evolocumab. The FOURIER population was mostly male (75 percent), which is a real evidence gap. Sex-stratified data published from FOURIER did not show a statistically significant difference in treatment effect between men and women, but the confidence intervals in the women's subgroup were wide. Clinicians and patients should know this is extrapolated, not definitively proven in women.

Sex-Specific Pharmacology: Does Your Biology Change How These Drugs Behave?

Ezetimibe pharmacokinetics are not substantially different between men and women in published data, and no dose adjustment is needed based on sex. Its glucuronidation-based metabolism does not interact meaningfully with endogenous estrogen or progestogen.

Evolocumab, as a large monoclonal antibody, follows pharmacokinetic patterns typical of biologics. Body weight affects volume of distribution, and women on average have lower body weight than men in most clinical populations. Population PK modeling from evolocumab development studies suggested that weight was a modest predictor of trough concentrations, but the approved doses were not adjusted by weight and the LDL-lowering effect was consistent across body weight subgroups in FOURIER.

Neither drug has meaningful interactions with hormonal contraception, menopausal hormone therapy, or thyroid replacement. However, hypothyroidism is itself a secondary cause of hypercholesterolemia, and postpartum thyroiditis affects up to 10 percent of women in the first year after delivery. If your LDL has jumped postpartum, thyroid status should be checked before escalating lipid therapy.

Pregnancy and Lactation Safety: This Section Is Not Optional

Both ezetimibe and evolocumab carry warnings against use in pregnancy. If you are trying to conceive, currently pregnant, or breastfeeding, neither drug should be part of your regimen without explicit clinician guidance.

Ezetimibe in Pregnancy

Ezetimibe is classified as contraindicated in pregnancy. The FDA label states that ezetimibe caused skeletal malformations in animal studies at exposures above the human therapeutic dose, and no adequate controlled studies exist in pregnant women. Because cholesterol is required for fetal development, reducing intestinal cholesterol absorption during pregnancy carries theoretical fetal risk. Stop ezetimibe before attempting conception and do not restart until you have finished breastfeeding, since animal data show ezetimibe passes into breast milk and its effect on nursing infants is unknown.

Evolocumab in Pregnancy

Evolocumab also lacks adequate human pregnancy data. The Repatha prescribing information notes that animal studies at high doses showed no adverse developmental outcomes, but IgG antibodies cross the placenta, and fetal PCSK9 pathways are active and may play a role in fetal lipid metabolism and organ development. There is no established human safety signal yet, but there is also no reassuring human dataset. Evolocumab should be discontinued before planned conception.

Contraception Requirements

Neither ezetimibe nor evolocumab is a known teratogen at the level of, for example, statins or warfarin, but both carry enough uncertainty that reliable contraception is expected during treatment in women of reproductive potential. If you are using either drug and your contraceptive situation changes (method failure, desire to conceive), discuss your lipid treatment plan with your cardiologist or internist before stopping or continuing.

Lactation

Human lactation data for both drugs is absent or extremely limited. Ezetimibe's animal data suggest milk transfer. Evolocumab, as a large IgG antibody (~144 kDa), has low expected oral bioavailability in a nursing infant, but this has not been formally studied in humans. The conservative recommendation from most guidelines is to avoid both drugs during breastfeeding and to consider the risk-benefit carefully if cardiovascular risk is severe.

Who Should Use Ezetimibe (and Who Should Switch to Evolocumab)

Ezetimibe Is Usually the Right Starting Point If You

• Are on a statin but have not reached your LDL goal (typically <70 mg/dL for high risk, <55 mg/dL for very high risk)
• Have moderate cardiovascular risk or primary prevention needs
• Cannot afford PCSK9 inhibitor pricing and lack adequate insurance coverage
• Have familial hypercholesterolemia at the milder end of the spectrum and statin plus ezetimibe gets you to goal
• Are in perimenopause and experiencing a first-time LDL rise that puts you above goal

The 2022 ACC/AHA Guideline on Cardiovascular Prevention recommends ezetimibe as the preferred first add-on to statin therapy before considering a PCSK9 inhibitor, largely due to cost and the availability of generic ezetimibe.

Evolocumab Is Appropriate If You

• Have established ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) and LDL remains above 70 mg/dL on maximally tolerated statin plus ezetimibe
• Have heterozygous or homozygous familial hypercholesterolemia with LDL that cannot be controlled by oral agents alone
• Are statin-intolerant and ezetimibe alone does not bring LDL to goal
• Had an acute coronary syndrome and are at very high recurrent event risk, where faster and deeper LDL lowering is the goal

Who Is Not an Ideal Candidate for Either Drug Right Now

Women who are pregnant, actively trying to conceive, or breastfeeding should pause both drugs. Women with secondary hypercholesterolemia from untreated hypothyroidism, nephrotic syndrome, or biliary obstruction need the underlying condition addressed first.

Switching Between Ezetimibe and Evolocumab: Practical Guide

Switching between these drugs, or adding one to the other, does not require a washout period. Ezetimibe's intestinal mechanism and evolocumab's hepatic PCSK9 inhibition are completely distinct, and the two can be used simultaneously.

Scenarios Where You Might Switch or Add

Scenario 1: On ezetimibe, not at LDL goal. The most common next step is to add evolocumab rather than replace ezetimibe. Using both together produces additive LDL lowering on top of statin background. There is no pharmacological reason to stop ezetimibe when starting evolocumab.

Scenario 2: On evolocumab, considering step-down. Some insurers require a step-therapy fail of ezetimibe before approving evolocumab. If your ASCVD risk is high enough to warrant evolocumab but cost or access is a barrier, your clinician may need to document prior ezetimibe use. Step-down from evolocumab to ezetimibe alone is rarely clinically appropriate in very high-risk women, since ezetimibe's 15 to 20 percent LDL reduction will not replicate the 59 percent reduction from evolocumab.

Scenario 3: Statin intolerance. If you are statin-intolerant, ezetimibe alone lowers LDL modestly. For women with FH or very high cardiovascular risk who cannot tolerate any statin, evolocumab monotherapy is appropriate and approved.

Scenario 4: Pregnancy planning. Both drugs need to stop. If you are currently on evolocumab for FH or very high-risk ASCVD and planning pregnancy, your clinician may consider bile acid sequestrants (such as colesevelam) as the only oral lipid-lowering option with a better safety profile in pregnancy, though even that evidence is limited. This requires a cardiology or maternal-fetal medicine consultation.

Step-by-Step Switching Protocol

1. Check your current LDL-C with a fasting lipid panel before any change.
2. Confirm your cardiovascular risk tier (ACC/AHA risk calculator or confirmed ASCVD/FH diagnosis).
3. If adding evolocumab to ezetimibe: no washout. Start evolocumab at your next injection date.
4. If replacing ezetimibe with evolocumab: stop ezetimibe the day you begin evolocumab. Recheck LDL in 4 to 8 weeks.
5. If stepping down from evolocumab to ezetimibe (e.g., pregnancy planning or cost): stop evolocumab, start ezetimibe the following day. Expect LDL to rise substantially. Recheck lipids in 6 weeks.
6. Notify your prescriber of any switch; prior authorization for evolocumab may require documentation of ezetimibe trial.

Side Effects: What Women Report

Ezetimibe Side Effects

Ezetimibe is generally well tolerated. The most common adverse effect is mild gastrointestinal discomfort. Elevated liver enzymes can occur, particularly when used with a statin, so baseline liver function testing is standard. Myopathy risk is not significantly elevated by ezetimibe alone, but any new muscle pain on a statin-ezetimibe combination should be evaluated.

Women in perimenopause sometimes attribute joint aches or fatigue to ezetimibe when these symptoms may overlap with hormonal changes. A clinical assessment distinguishing drug-related from menopause-transition symptoms matters before stopping a medication that may be protecting your heart.

Evolocumab Side Effects

The most commonly reported adverse effects in FOURIER were nasopharyngitis, upper respiratory tract infection, and injection site reactions. Neurocognitive concerns were raised early in PCSK9 inhibitor development, but the dedicated EBBINGHAUS trial found no significant cognitive impairment with evolocumab versus placebo. Injection site bruising is more common in women on concurrent anticoagulants; rotating injection sites helps.

The Cost Reality and Insurance Field

Ezetimibe is available as a generic. Monthly out-of-pocket cost is typically $10 to $30. Evolocumab's list price is approximately $5,600 per year, though manufacturer copay cards and insurance can reduce this substantially for eligible women. Prior authorization criteria vary by insurer, but most require documented statin plus ezetimibe failure before approving a PCSK9 inhibitor, which directly affects switching decisions.

If cost is a barrier, ask your clinician about the Amgen SupportPlus program, which may reduce evolocumab cost for commercially insured patients to as little as $0 per month.

A Note on Evidence Gaps in Women

The IMPROVE-IT trial enrolled approximately 24 percent women. FOURIER enrolled approximately 25 percent women. Neither trial was designed or powered to detect sex-specific differences in cardiovascular outcomes. Published subgroup analyses show consistent directional benefit in women, but the confidence intervals are wide. This is a real limitation. The ACC/AHA guidelines that guide prescribing were built primarily on data from predominantly male trial populations. That does not mean these drugs do not work in women. It means that some of what we apply to women is extrapolated from men, and you deserve to know that.

"Women have been underrepresented in major cardiovascular outcome trials for decades, and this limits our ability to give sex-specific risk guidance with the same confidence we have in men," according to a 2020 analysis in Circulation.